Peer Exchange


Chronic Lymphocytic Leukemia: Evolving Management With New Data From EHA 2025

June 30th 2025

Callie Coombs, MD; Nicole Lamanna, MD; Sameer A. Parikh, MBBS; Joanna M. Rhodes, MD, MSCE; and Mazyar Shadman, MD, MPH, discuss how to optimize chronic lymphocytic leukemia (CLL) treatment by incorporating prognostic biomarkers like TP53 status and IGHV mutation testing into therapy selection, weighing the benefits of continuous Bruton tyrosine kinase inhibitor therapy vs fixed-duration oral doublet regimens, managing treatment toxicities and resistance patterns, and sequencing therapies in the relapsed/refractory setting based on emerging clinical trial data presented at the European Hematology Association 2025 Congress (EHA 2025).

Expert Insights On An Evolving Treatment Landscape In Multiple Myeloma: Updates From EHA 2025

June 30th 2025

Sagar Lonial, MD, FACP, FASCO; Adrianna Rossi, MD; Ajay K. Nooka, MD, MPH, FACP; and Cesar Rodriguez, MD, discuss how evolving treatment strategies in multiple myeloma are shifting toward quadruplet therapy regimens for newly diagnosed patients, with CAR T-cell therapy being used increasingly in earlier lines of treatment for high-risk disease. They emphasize the importance of achieving MRD negativity and personalizing treatment approaches based on patient fitness rather than strict transplant eligibility criteria.

Metastatic Castration-Sensitive Prostate Cancer: Evolving Management With New Data from ASCO 2025

June 30th 2025

Petros Grivas, MD, PhD; Rana R. McKay, MD; Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS discuss how to personalize treatment intensification in metastatic castration-sensitive prostate cancer by considering clinical factors like disease volume, patient fitness, genomic biomarkers, and emerging trial data to guide decisions between doublet versus triplet therapy regimens.

Optimizing Early-Stage NSCLC Management Through Multidisciplinary Strategies: ASCO 2025

June 27th 2025

Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, MD; Brendon Stiles, MD; and Mara Antonoff, MD, FACS, discuss how the evolving landscape of early-stage non–small cell lung cancer (NSCLC) treatment has been transformed by neoadjuvant and perioperative chemoimmunotherapy approaches, with recent data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from CheckMate 816 and CheckMate 77T demonstrating significant overall survival benefits while highlighting the critical importance of multidisciplinary collaboration, biomarker-guided personalization, and managing surgical attrition rates to optimize patient outcomes.

ASCO 2025: Modern Approaches to Metastatic Melanoma: Navigating the Treatment Landscape

June 25th 2025

Panelists discuss the significant advancements in metastatic melanoma treatment over the past decade, including targeted therapies and immunotherapy, to help clinicians navigate the evolving therapeutic landscape and improve patient outcomes.

MATTERHORN Spotlight—Shaping the Treatment Horizon for Gastric/Gastroesophageal Junction (GEJ) Cancers

June 25th 2025

Sam Klempner, MD; Michael K. Gibson, MD, PhD; Kaitlyn Kelly, MD, MAS; and Nataliya Uboha, MD, PhD, discuss how the positive results from the phase 3 MATTERHORN trial, which demonstrated that adding durvalumab to perioperative FLOT chemotherapy significantly improved event-free survival in patients with resectable gastric and gastroesophageal junction cancers, establishes a new standard of care that they plan to implement in clinical practice while addressing practical considerations around patient selection, multidisciplinary coordination, and managing the toxicity profile of this combination regimen.

ASCO 2025: Optimizing Breast Cancer Surveillance With ctDNA Testing: Transforming Early Detection and Recurrence Monitoring

June 24th 2025

Panelists discuss the evolving landscape of breast cancer surveillance, focusing on circulating tumor DNA testing for molecular residual disease detection, recent clinical data supporting its use, and practical strategies for integrating this technology into posttreatment monitoring.

Advancements in the Treatment and Management of SCLC: Updates From ASCO 2025

June 23rd 2025

Panelists discussed evolving strategies in limited-stage and extensive-stage small cell lung cancer (LS-SCLC and ES-SCLC), including the integration of consolidation durvalumab in LS-SCLC, emerging first-line chemoimmunotherapy regimens in ES-SCLC, maintenance strategies such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305), and the promising future role of novel agents like T-cell engagers, antibody-drug conjugates, and B7-H3–targeted therapies (including DeLLphi-304) in reshaping the treatment landscape.

ASCO 2025: Expert Perspectives in Gastrointestinal Stromal Tumor Treatment

June 20th 2025

Shreyaskumar R. Patel, MD; Priscilla Merriam, MD; Richard F. Riedel, MD; and Gina Z. D'Amato, MD, discuss how gastrointestinal stromal tumors require comprehensive mutational analysis to guide targeted kinase inhibitor therapy, emphasizing the importance of patient adherence, proactive adverse effect management, and maintaining some form of kinase inhibition even after progression to maximize disease control and quality of life.

Oncodrivers in Advanced or Metastatic NSCLC: Current and Future Standards of Care

June 17th 2025

Joshua Sabari, MD; Christine Bestvina, MD; Hatim Husain, MD; and Julia Rotow, MD, discuss how targeted therapies for KRAS G12C and ALK::ROS1 fusion-positive advanced non–small cell lung cancer are evolving from second-line treatments to promising frontline combinations with immunotherapy, emphasizing the critical importance of comprehensive biomarker testing and the management of unique toxicity profiles as these next-generation inhibitors demonstrate improved efficacy and central nervous system penetration.

EGFR mutated NSCLC: Treatment Advances and Highlights from ASCO 2025

June 17th 2025

Panelists discuss the latest data on first-line treatment options for EGFR-mutated NSCLC, including CNS efficacy, and explore strategies for managing adverse events and sequencing therapies to optimize long-term outcomes.

Advancements in Treatment Selection and Sequencing in HER2-Positive Metastatic Breast Cancer: Insights from ASCO 2025

June 17th 2025

Heather McArthur, MD; Laura Huppert, MD; Ruta Rao, MD; William J. Gradishar, MD, FACP; and VK Gadi, MD, PhD, discuss how recent ASCO 2025 data from DESTINY-Breast09 and other studies are reshaping first-line treatment decisions for HER2-positive metastatic breast cancer, with experts debating optimal sequencing strategies between trastuzumab deruxtecan (T-DXd), the CLEOPATRA regimen, and CDK4/6 inhibitor combinations while considering patient-specific factors like central nervous system metastases, hormone receptor status, and quality of life preferences.

Gynecological Cancers: Treatment Updates and Expert Perspectives

June 17th 2025

Leslie M. Randall, MD; Thomas C. Krivak, MD; Rebecca C. Arend, MD, MPH; Tara Berman, MD, MS, Gottfried E. Konecny, MD discusses how molecular testing and biomarker-driven treatment strategies are revolutionizing gynecologic oncology across ovarian, cervical, and endometrial cancers.

HR+ Breast Cancer: Treatment Advances and Highlights from ASCO 2025

June 16th 2025

Rebecca Shatsky, MD; Rita Nanda, MD; Kelly McCann, MD, PhD; Nusayba Bagegni, MD; and Alexis LeVee, MD,discuss how recent advances in hormone receptor–positive breast cancer treatment, including oral SERDs such as elacestrant, PI3K pathway inhibitors, and antibody-drug conjugates such as T-DXd, are being integrated into clinical practice based on biomarkers such as ESR1 mutations and HER2-low expression while addressing key sequencing decisions and resistance mechanisms in the evolving therapeutic landscape.

ASCO 2025: Current Insights and Emerging Approaches in Managing Treatment-Resistant Metastatic Colorectal Cancer

June 16th 2025

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS, MD, and Katrina S. Pedersen, MD discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for MSI-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma

June 13th 2025

Luciano Costa, MD, PhD; Jing Christine Ye, MD, MSc; Samer Al Hadidi, MD, MS; and Binod Dhakal, MD, discuss how the multiple myeloma treatment landscape has evolved with quadruplet therapies becoming standard for newly diagnosed patients regardless of transplant eligibility, CAR T and bispecific antibodies showing promise for earlier use in relapsed/refractory disease, and emerging dual-targeting therapies potentially offering cure for some patients rather than just prolonged treatment.

Clinical Perspectives on the Treatment of Neuroendocrine Tumors

June 13th 2025

Daneng Li, MD; Lowell B. Anthony, MD, FACP; Christopher Lieu, MD; and Chandrikha Chandrasekharan, MBBS, discuss how the treatment landscape for neuroendocrine tumors has evolved significantly over the past few decades with the introduction of multiple therapeutic options including somatostatin analogs, targeted therapies like everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), and the recent approval of cabozantinib, which provides new sequencing opportunities and fills treatment gaps for heavily pretreated patients while emphasizing the importance of individualized patient care and shared decision-making in this complex disease.

Optimizing CTCL Care: Expert Perspectives on Patient-Centered Approaches

June 4th 2025

David C. Fisher, MD; Lauren C. Pinter-Brown, MD; Barbara Pro, MD, and Sima Rozati, MD, PhD discuss how to optimize cutaneous T-cell lymphoma treatment through multidisciplinary care, compartment-specific therapy selection, management of treatment-related complications like mogamalizumab-associated rash, and strategic use of combination therapies while addressing critical unmet needs including biomarker development and improved quality of life measures.

Redefining Allogeneic Transplants & Cellular Therapy: Key Takeaways from EBMT 2025

April 22nd 2025

Experts discuss key indications for alloHSCT and emerging GVHD prophylaxis strategies, as well as explore a novel investigational allogeneic T-cell immunotherapy, Orca-T® and its clinical impact in the field of transplantation.

Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.

Optimizing Early-Stage NSCLC Management: A Multidisciplinary Perspective

April 8th 2025

Vamsidhar Velcheti, MD, MBA, FASCO, FACP, FCCP; Jessica Donington, MD, MSCR; Jaspal Singh, MD; and Joshua Sabari, MD, discuss how optimizing early-stage non–small cell lung cancer (NSCLC) management through a multidisciplinary approach enhances treatment outcomes and improves patient care.

x